Literature DB >> 28623510

The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.

Yan Shen1, Xingfang Guo1, Chao Han1, Fang Wan1, Kai Ma1, Shiyi Guo1, Luxi Wang1, Yun Xia1, Ling Liu1, Zhicheng Lin2, Jinsha Huang1, Nian Xiong1, Tao Wang3.   

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder implicitly marked by the substantia nigra dopaminergic neuron degeneration and explicitly characterized by the motor and non-motor symptom complexes. Apart from the nigrostriatal dopamine depletion, the immune and endocrine study findings are also frequently reported, which, in fact, have helped to broaden the symptom spectrum and better explain the pathogenesis and progression of PD. Nevertheless, based on the neural, immune, and endocrine findings presented above, it is still difficult to fully recapitulate the pathophysiologic process of PD. Therefore, here, in this review, we have proposed the neuroimmunoendocrine (NIE) modulatory network in PD, aiming to achieve a more comprehensive interpretation of the pathogenesis and progression of this disease. As a matter of fact, in addition to the classical motor symptoms, NIE modulatory network can also underlie the non-motor symptoms such as gastrointestinal, neuropsychiatric, circadian rhythm, and sleep disorders in PD. Moreover, the dopamine (DA)-melatonin imbalance in the retino-diencephalic/mesencephalic-pineal axis also provides an alternative explanation for the motor complications in the process of DA replacement therapy. In conclusion, the NIE network can be expected to deepen our understanding and facilitate the multi-dimensional management and therapy of PD in future clinical practice.

Entities:  

Keywords:  Dopaminergic receptor (DR); Hypothalamus; Neuroendocrine; Neuroinflammation; Pineal gland; α-Synuclein (SNCA)

Mesh:

Substances:

Year:  2017        PMID: 28623510     DOI: 10.1007/s00018-017-2549-2

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  298 in total

1.  Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.

Authors:  Camila Andrade Mendes Medeiros; Pedro Felipe Carvalhedo de Bruin; Lívia Ariane Lopes; Maria Cecília Magalhães; Maria de Lourdes Seabra; Veralice Meireles Sales de Bruin
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

2.  Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.

Authors:  He-Jin Lee; Ji-Eun Suk; Eun-Jin Bae; Jung-Ho Lee; Seung R Paik; Seung-Jae Lee
Journal:  Int J Biochem Cell Biol       Date:  2008-01-20       Impact factor: 5.085

3.  Dopamine regulates melanopsin mRNA expression in intrinsically photosensitive retinal ganglion cells.

Authors:  Katsuhiko Sakamoto; Cuimei Liu; Manami Kasamatsu; Nikita V Pozdeyev; P Michael Iuvone; Gianluca Tosini
Journal:  Eur J Neurosci       Date:  2005-12       Impact factor: 3.386

4.  Body mass index in Parkinson's disease: a meta-analysis.

Authors:  Marjolein A van der Marck; Heleen C Dicke; Ergun Y Uc; Zippora H A Kentin; George F Borm; Bastiaan R Bloem; Sebastiaan Overeem; Marten Munneke
Journal:  Parkinsonism Relat Disord       Date:  2011-11-18       Impact factor: 4.891

5.  Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

Authors:  R Pahwa; M A Stacy; S A Factor; K E Lyons; F Stocchi; B P Hersh; L W Elmer; D D Truong; N L Earl
Journal:  Neurology       Date:  2007-04-03       Impact factor: 9.910

6.  The hypothalamus in Parkinson disease.

Authors:  J W Langston; L S Forno
Journal:  Ann Neurol       Date:  1978-02       Impact factor: 10.422

7.  Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.

Authors:  Iwona Kurkowska-Jastrzebska; Tomasz Litwin; Ilona Joniec; Agnieszka Ciesielska; Adam Przybyłkowski; Andrzej Członkowski; Anna Członkowska
Journal:  Int Immunopharmacol       Date:  2004-10       Impact factor: 4.932

8.  (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury.

Authors:  Rui Li; Yuan-Gui Huang; Du Fang; Wei-Dong Le
Journal:  J Neurosci Res       Date:  2004-12-01       Impact factor: 4.164

9.  Nurr1 expression and its modulation in microglia.

Authors:  Xiaolan Fan; Guangrui Luo; Ming Ming; Pu Pu; Liang Li; Dehua Yang; Weidong Le
Journal:  Neuroimmunomodulation       Date:  2009-02-24       Impact factor: 2.492

10.  MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration.

Authors:  Carolina Cebrián; Fabio A Zucca; Pierluigi Mauri; Julius A Steinbeck; Lorenz Studer; Clemens R Scherzer; Ellen Kanter; Sadna Budhu; Jonathan Mandelbaum; Jean P Vonsattel; Luigi Zecca; John D Loike; David Sulzer
Journal:  Nat Commun       Date:  2014-04-16       Impact factor: 14.919

View more
  6 in total

1.  The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson's disease via the microglial NLRP3 inflammasome.

Authors:  Liang Kou; Xiaosa Chi; Yadi Sun; Chao Han; Fang Wan; Junjie Hu; Sijia Yin; Jiawei Wu; Yunna Li; Qiulu Zhou; Wenkai Zou; Nian Xiong; Jinsha Huang; Yun Xia; Tao Wang
Journal:  J Neuroinflammation       Date:  2022-06-06       Impact factor: 9.587

2.  A Gutsy Move for Cell-Based Regenerative Medicine in Parkinson's Disease: Targeting the Gut Microbiome to Sequester Inflammation and Neurotoxicity.

Authors:  Jea-Young Lee; Julian P Tuazon; Sydney Corey; Brooke Bonsack; Sandra Acosta; Jared Ehrhart; Paul R Sanberg; Cesario V Borlongan
Journal:  Stem Cell Rev Rep       Date:  2019-10       Impact factor: 6.692

3.  Elevated Plasma Melatonin Levels Are Correlated With the Non-motor Symptoms in Parkinson's Disease: A Cross-Sectional Study.

Authors:  Linyi Li; Zhenxiang Zhao; Jianjun Ma; Jinhua Zheng; Shen Huang; Shiyu Hu; Qi Gu; Siyuan Chen
Journal:  Front Neurosci       Date:  2020-05-19       Impact factor: 4.677

4.  Mitochonic acid 5 regulates mitofusin 2 to protect microglia.

Authors:  Jian Tan; Shuang-Xi Chen; Qing-Yun Lei; Shan-Qing Yi; Na Wu; Yi-Lin Wang; Zi-Jian Xiao; Heng Wu
Journal:  Neural Regen Res       Date:  2021-09       Impact factor: 5.135

5.  Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Disease: A Meta-Analysis.

Authors:  Wenjie Sun; Junqiang Yan; Jiannan Wu; Hongxia Ma
Journal:  Med Sci Monit       Date:  2022-01-07

6.  Mitochonic acid 5 activates the MAPK-ERK-yap signaling pathways to protect mouse microglial BV-2 cells against TNFα-induced apoptosis via increased Bnip3-related mitophagy.

Authors:  Qingyun Lei; Jian Tan; Shangqing Yi; Na Wu; Yilin Wang; Heng Wu
Journal:  Cell Mol Biol Lett       Date:  2018-04-05       Impact factor: 5.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.